TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Brief Summary: Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).

Primary Objective of the study:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab in comparison with ezetimibe after 24 weeks of treatment in participants with hypercholesterolemia.

Secondary Objectives:

* To evaluate the effect of alirocumab in comparison with ezetimibe on LDL-C at other time points
* To evaluate the effect of alirocumab on other lipid parameters
* To evaluate the safety and tolerability of alirocumab


Options:
A: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo (for Alirocumab) | Arm Label: Alirocumab 75/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for Ezetimibe) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Ezetimibe); Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical Study of Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension
Brief Summary: The objective of this study is to demonstrate that the MDT-2211 renal denervation system is a safe and effective treatment for uncontrolled hypertension subjects despite treatment with 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic, as best available antihypertensive therapy


Options:
A: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Device: MDT-2211 Renal Denervation System | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MDT-2211 Renal Denervation System; Assigned to Arm(s): Renal denervation
B: Intervention Type: DEVICE; Name: Symplicty(TM) Catheter System; Assigned to Arm(s): N/A
C: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: Renal sympathetic denervation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Renal sympathetic denervation; Assigned to Arm(s): Renal sympathetic denervation
D: Arm Label: Circumferential PVI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: Circumferential PVI+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PVI+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): Circumferential PVI | Intervention Type: PROCEDURE; Name: Circumferential PVI+renal denervation; Assigned to Arm(s): Circumferential PVI+renal denervation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical Study of Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension
Brief Summary: The objective of this study is to demonstrate that the MDT-2211 renal denervation system is a safe and effective treatment for uncontrolled hypertension subjects despite treatment with 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic, as best available antihypertensive therapy


Options:
A: Arm Label: Renal artery ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal artery ablation | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Procedure: Renal angiography | Intervention Type: PROCEDURE; Name: Renal artery ablation; Assigned to Arm(s): Renal artery ablation | Intervention Type: PROCEDURE; Name: Renal angiography; Assigned to Arm(s): Sham
B: Arm Label: Renal Denervation Treatment; Type: N/A; Interventions: Device: Medtronic Renal Denervation System | Intervention Type: DEVICE; Name: Medtronic Renal Denervation System; Assigned to Arm(s): Renal Denervation Treatment
C: Arm Label: Rapid Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Covidien OneShot™ System | Intervention Type: DEVICE; Name: Covidien OneShot™ System; Assigned to Arm(s): Rapid Renal Denervation
D: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Device: MDT-2211 Renal Denervation System | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MDT-2211 Renal Denervation System; Assigned to Arm(s): Renal denervation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 Using an Environmental Exposure Chamber in Subjects With House Dust Induced Allergic Rhinitis/Rhinoconjunctivitis
Brief Summary: The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in adults. The primary hypothesis is that administration of MK-8237, compared to placebo, results in dose-related improvement in the average total nasal symptom score (TNSS) determined during environmental exposure chamber (EEC) challenge.


Options:
A: Intervention Type: DRUG; Name: ALK HDM tablet; Assigned to Arm(s): N/A
B: Arm Label: SLIT; Type: EXPERIMENTAL; Interventions: Biological: sublingual immunotherapy | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: sublingual immunotherapy; Assigned to Arm(s): SLIT | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MK-8237 6 Developmental Units (DU); Type: EXPERIMENTAL; Interventions: Drug: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Drug: MK-8237 12 DU | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 Developmental Units (DU) | Intervention Type: DRUG; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU
D: Arm Label: Oral mucosal immunoprophylaxis (OMIP); Type: EXPERIMENTAL; Interventions: Biological: Oral mucosal immunoprophylaxis (OMIP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Oral mucosal immunoprophylaxis (OMIP); Assigned to Arm(s): Oral mucosal immunoprophylaxis (OMIP) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer
Brief Summary: The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.


Options:
A: Arm Label: Intraperitoneal bevacizumab+ carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: paclitaxel | Arm Label: Intraperitoneal carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin
B: Arm Label: paclitaxel and pazopanib; Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: pazopanib | Arm Label: paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): paclitaxel, paclitaxel and pazopanib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): paclitaxel and pazopanib
C: Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A
D: Arm Label: BIBF1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF1120 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BIBF1120; Assigned to Arm(s): BIBF1120 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer
Brief Summary: The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.


Options:
A: Arm Label: Arm I (adjuvant chemotherapy suboptimally debulked); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (neoadjuvant chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy)
B: Arm Label: paclitaxel and pazopanib; Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: pazopanib | Arm Label: paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): paclitaxel, paclitaxel and pazopanib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): paclitaxel and pazopanib
C: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
D: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer
Brief Summary: The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.


Options:
A: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oglufanide disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
B: Arm Label: paclitaxel and pazopanib; Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: pazopanib | Arm Label: paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): paclitaxel, paclitaxel and pazopanib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): paclitaxel and pazopanib
C: Arm Label: Tivozanib; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tivozanib; Assigned to Arm(s): Tivozanib
D: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Pediatric Cancer Patients With Solid Tumor Trial
Brief Summary: The aim of this randomized controlled trial on Physical Activity and Pediatric Cancer (PAPEC) is to assess the impact of an exercise program intervention in pediatric cancer patients undergoing chemotherapy for solid tumors. The investigators hypothesized the intervention will have a beneficial effect on the study outcomes.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: exercise | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): A
B: Arm Label: treatment (exercise); Type: EXPERIMENTAL; Interventions: Other: exercise training | Arm Label: control (usual care); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise training; Assigned to Arm(s): treatment (exercise)
C: Arm Label: Active video games; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise based on active video gaming | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise based on active video gaming; Assigned to Arm(s): Active video games
D: Arm Label: Exercise (EX); Type: EXPERIMENTAL; Interventions: Other: EXERCISE (EX) | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: EXERCISE (EX); Assigned to Arm(s): Exercise (EX) | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost
Brief Summary: Although gains have been made in achieving the health-related Millennium Development Goals (MDG), much is still needed in countries affected by high levels of HIV/AIDS. Prevention of mother-to-child transmission (PMTCT) is a cornerstone strategy in reducing infant mortality from HIV. The study will employ a cluster randomized control trial (cRCT) with 26 health facilities randomized to two arms (intervention or control) to determine the effect of mobile phone technology on completion of key PMTCT milestones from antenatal to six weeks postpartum. The study will examine the acceptability, effectiveness, and cost of implementing a PMTCT-focused mHealth strategy among HIV-infected pregnant women, health workers, and male partners.


Options:
A: Arm Label: Intense follow up; Type: EXPERIMENTAL; Interventions: Behavioral: intense follow up | Arm Label: standard follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intense follow up; Assigned to Arm(s): Intense follow up
B: Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone | Arm Label: Reminders + compliance-linked incentives; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone, Behavioral: Compliance-linked incentives | Intervention Type: BEHAVIORAL; Name: Reminders alone; Assigned to Arm(s): Reminders + compliance-linked incentives, Reminders alone | Intervention Type: BEHAVIORAL; Name: Compliance-linked incentives; Assigned to Arm(s): Reminders + compliance-linked incentives
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
D: Arm Label: Control; Type: N/A; Interventions: Behavioral: Control | Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost
Brief Summary: Although gains have been made in achieving the health-related Millennium Development Goals (MDG), much is still needed in countries affected by high levels of HIV/AIDS. Prevention of mother-to-child transmission (PMTCT) is a cornerstone strategy in reducing infant mortality from HIV. The study will employ a cluster randomized control trial (cRCT) with 26 health facilities randomized to two arms (intervention or control) to determine the effect of mobile phone technology on completion of key PMTCT milestones from antenatal to six weeks postpartum. The study will examine the acceptability, effectiveness, and cost of implementing a PMTCT-focused mHealth strategy among HIV-infected pregnant women, health workers, and male partners.


Options:
A: Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone | Arm Label: Reminders + compliance-linked incentives; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone, Behavioral: Compliance-linked incentives | Intervention Type: BEHAVIORAL; Name: Reminders alone; Assigned to Arm(s): Reminders + compliance-linked incentives, Reminders alone | Intervention Type: BEHAVIORAL; Name: Compliance-linked incentives; Assigned to Arm(s): Reminders + compliance-linked incentives
B: Arm Label: Text-Based Adherence Game; Type: EXPERIMENTAL; Interventions: Behavioral: Text-Based Adherence Game, Behavioral: Standard of Care (SOC) | Arm Label: Standard of Care (SOC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care (SOC) | Intervention Type: BEHAVIORAL; Name: Text-Based Adherence Game; Assigned to Arm(s): Text-Based Adherence Game | Intervention Type: BEHAVIORAL; Name: Standard of Care (SOC); Assigned to Arm(s): Standard of Care (SOC), Text-Based Adherence Game
C: Arm Label: Control, standard care for HPV vaccine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention, computer reminder system; Type: EXPERIMENTAL; Interventions: Behavioral: Computer reminder system | Intervention Type: BEHAVIORAL; Name: Computer reminder system; Assigned to Arm(s): Intervention, computer reminder system
D: Arm Label: Control; Type: N/A; Interventions: Behavioral: Control | Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention

Answer: D